Adverse somatic mutations including ASXL1, RUNX1, TP53 or EZH2 significantly impact on the prognosis of MDS patients [1] and established therapeutic concepts have only limited efficacy in this patient population [2–4]. The gene discussed is ASXL1; the disease is myelodysplastic syndrome.